We are live on ! Find out more
SC

Sophrosyne Capital Portfolio holdings

AUM $11.5M
1-Year Est. Return 17.82%
This Fund
S&P 500
This Quarter Est. Return
+0.69%
1 Year Est. Return
+17.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$98.2M
AUM Growth
-$16M
Cap. Flow
-$12.8M
Cap. Flow %
-13.02%
Top 10 Hldgs %
57.17%
Holding
92
New
14
Increased
16
Reduced
24
Closed
27

Top Buys

Rank Stock Value
1
DRRX
DURECT Corp
DRRX
+$1.78M
2
BKNG icon
Booking.com
BKNG
+$1.68M
3
RTK
Rentech, Inc.
RTK
+$1.66M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$1.33M
5
CDZI icon
Cadiz
CDZI
+$1.16M

Top Sells

Rank Stock Value
1
SYT
Syngenta Ag
SYT
+$6.05M
2
LSAK icon
Lesaka Technologies
LSAK
+$3.8M
3
TLPH icon
Talphera
TLPH
+$2.99M
4
CUTR
Cutera, Inc.
CUTR
+$1.56M
5
DRTX
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
+$1.42M

Sector Composition

Rank Sector Weight
1 Healthcare 44.84%
2 Technology 18.47%
3 Financials 8.1%
4 Communication Services 7.26%
5 Materials 6.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAP icon
76
SAP
SAP
$255B
– –
-8,200
Closed -$668K
SB icon
77
Safe Bulkers
SB
$857M
– –
-20,161
Closed -$192K
SNOA icon
78
Sonoma Pharmaceuticals
SNOA
$6.37M
– –
-154
Closed -$522K
STRM
79
DELISTED
Streamline Health Solutions
STRM
– –
-13,220
Closed -$998K
TLPH icon
80
Talphera
TLPH
$63.8M
– –
-12,449
Closed -$2.99M
CUTR
81
DELISTED
Cutera, Inc.
CUTR
– –
-139,689
Closed -$1.56M
MMAT
82
DELISTED
Meta Materials Inc. Common Stock
MMAT
– –
-73
Closed -$74K
HNGR
83
DELISTED
Hanger Inc.
HNGR
– –
-26,233
Closed -$882K
VWTR
84
DELISTED
Vidler Water Resouces, Inc. Common Stock
VWTR
– –
-12,600
Closed -$327K
FPRX
85
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-22,300
Closed -$438K
SNMX
86
DELISTED
Senomyx, Inc.
SNMX
– –
-44,700
Closed -$477K
SYT
87
DELISTED
Syngenta Ag
SYT
– –
-80,050
Closed -$6.05M
OME
88
DELISTED
Omega Protein
OME
– –
-3,700
Closed -$45K
TBRA
89
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
– –
-2,744
Closed -$310K
ACFN
90
DELISTED
Acorn Energy Inc
ACFN
– –
-311,700
Closed -$1.05M
DRTX
91
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
– –
-105,500
Closed -$1.42M
GCVRZ
92
DELISTED
Sanofi Contingent Value Rights
GCVRZ
– –
-488,100
Closed -$151K
1 2 3
4

Similar funds

SFM
Socratic Fund Management Short Hills, New Jersey $12M AUM 39.3% 1-Year Est. Return
IACGFA
IDG-Accel China Growth Fund Associates Central, Hong Kong $13.2M AUM 31.6% 1-Year Est. Return
LS
Lupo Securities Chicago, Illinois $13.3M AUM 1.59% 1-Year Est. Return
NGPI
N.G. Partners II Palo Alto, California $9.65M AUM 70.44% 1-Year Est. Return
AP
AGTC Partners Cambridge, Massachusetts $13.6M AUM 15.62% 1-Year Est. Return
GRP
Geologic Resource Partners Boston, Massachusetts $9.22M AUM 48.14% 1-Year Est. Return
NVPV
Norwest Venture Partners VIII Palo Alto, California $9.22M AUM
AC
Amiya Capital London, United Kingdom $14.3M AUM 4.61% 1-Year Est. Return

Sophrosyne Capital's Q2 2014 Portfolio in Review

As of Q2 2014, Sophrosyne Capital held 92 positions worth $98.2M, down 14% from $114M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sophrosyne Capital withdrew a net $12.8M in Q2 2014, closing 27 positions and reducing 24 holdings. Its most notable exit was Syngenta Ag, an estimated $6.05M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 47% a quarter earlier, followed by Technology and Financials.

Against the trend, Sophrosyne Capital opened a new position in DURECT Corp worth $2.31M.

  • Sophrosyne Capital's largest Q2 2014 buy was DURECT Corp: 126,902 shares worth $2.31M.
  • Sophrosyne Capital added most to Rentech, Inc. in Q2 2014, an estimated $1.66M increase.
  • Sophrosyne Capital's biggest Q2 2014 reduction was BioDelivery Sciences International, Inc., cutting an estimated $1.16M.
  • Sophrosyne Capital fully exited Syngenta Ag in Q2 2014, selling an estimated $6.05M.
  • Sophrosyne Capital's ten largest holdings make up 57% of its $98.2M portfolio in Q2 2014.
  • Sophrosyne Capital opened 14 new positions and closed 27 in Q2 2014.
  • Sophrosyne Capital's portfolio value fell 14% quarter-over-quarter to $98.2M.

Based on Sophrosyne Capital's 13F filing for Q2 2014, filed 14 Aug 2014.